Pre-operative injections of epoetin-α versus post-operative retransfusion of autologous shed blood in total hip and knee replacement: A prospective randomised clinical trial

Journal of Bone and Joint Surgery - Series B

Volumn 90, Issue 8, 2008, Pages 1079-1083

  Moonen, A F C M ^a   Thomassen, B J W ^a   Knoors, N T ^a   Van Os, J J ^a   Verburg, A D ^a   Pilot, P ^b  

^a Sittard Geleen Heerlen   (Netherlands)

^b REINIER DE GRAAF HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FERROFUMERATE; HEMOGLOBIN; IRON DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD AUTOTRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; FEMALE; HEALTH CARE COST; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; NAUSEA; OCCLUSIVE CEREBROVASCULAR DISEASE; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE RETENTION; WOUND FLUID; WOUND INFECTION;

AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION, AUTOLOGOUS; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOSTASIS, SURGICAL; HUMANS; INJECTIONS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROSPECTIVE STUDIES; STATISTICS AS TOPIC;

EID: 53649084986     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.90B8.20595     Document Type: Article

References (21)

1. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 1996;25:544-52.
2. de Andrade JR, Jove M, Landon G, et al. Baseline haemoglobin as a predictor of risk of transfusion and response to Epoetin alfa in orthopaedic surgery patients. Am J Orthop 1996;25:533-42.
3. Faris PM, Ritter MA. Epoetin alfa: a bloodless approach for the treatment of perioperative anemia. Clin Orthop 1998;357:60-7.
4. Weber EW, Slappendel R, Hémon Y, et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005;22:249-57.
5. Southern EP, Huo MH, Mehta JR, Keggi KJ. Unwashed wound drainage blood: what are we giving our patients? Clin Orthop 1995;320:235-46.
6. Strümper D, Weber EW, Gielen-Wijffels S, et al. Clinical efficacy of postoperative autologous transfusion of filtered shed blood in hip and knee arthroplasty. Transfusion 2004;44:1567-71.
7. Moonen AF, Knoors NT, van Os JJ, et al. Retransfusion of filtered shed blood in primary total hip and knee arthroplasty: a prospective randomised clinical trial. Transfusion 2007;47:379-84.
8. Smith LK, Williams DH, Langkamer VG. Post-operative blood salvage with autologous retransfusion in primary total hip replacement. J Bone Joint Surg [Br] 2007;89-B:1092-7.
9. Slappendel R, Dirksen R, Weber EW, van der Schaaf DB. An algorithm to reduce allogenic red blood cell transfusions for major orthopaedic surgery. Acta Orthop Scand 2003;74:569-75.
10. No authors listed. Pubmed. http://www.pubmed.com (date last accessed 26 June 2008).
11. Dripps RD, Lamont A, Eckenhoff JE. The role of anesthesia in surgical mortality. JAMA 1961;21:261-6.
12. Parvizi J, Mui A, Purtill JJ, et al. Total joint arthroplasty: when do fatal or nearfatal complications occur? J Bone Joint Surg [Am] 2007;89-A:27-32.
13. Vamvakas EC, Moore SB. Total potential frequency of autologous blood transfusion in Olmsted County, MN. Mayo Clin Proc 1995;70:37-44.
14. Pola E, Papaleo P, Santoliquido A, et al. Clinical factors associated with an increased risk of perioperative blood transfusion in nonanemic patients undergoing total hip arthroplasty. J Bone Joint Surg [Am] 2004;86-A:57-61.
15. Newman JH, Bowers M, Murphy J. The clinical advantages of autologous transfusion: a randomised controlled study after knee replacement. J Bone Joint Surg [Br] 1997;79-B:630-2.
16. Jaar B, Denis A, Viron B, et al. Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation. Am J Nephrol 1997;17:399-405.
17. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Eng J Med 2007;357:965-76.
18. No authors listed. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 1993;341:1227-32.
19. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip and joint arthroplasty: a randomized, controlled trial. Ann Intern Med 2000;133:845-54.
20. Salido JA, Marín LA, Gómez LA, Zorrilla P, Martinez C. Preoperative hemoglobin levels and the need for transfusion after prosthetic hip and knee surgery: analysis of predictive factors. J Bone Joint Surg [Am] 2002;84-A:216-20.
21. Sehat KR, Evans RL, Newman JH. Hidden blood loss following hip and knee arthroplasty: correct management of blood loss should take hidden loss into account. J Bone Joint Surg [Br] 2004;86-B:561-5.